American cosmetic company Peter Roth LLC has resolved a lawsuit filed by the Tennessee Attorney General’s office after allegations that their products contained none-FDA approved ingredients.
The company was alleged to have included a derivative of the drug compound prostaglandin in eye shadow products “Lashes to Die For”, “Brows to Die For” and “Lashes to Die For Platinum.”
The state says that using this potent hormone-like chemical without authorization and without informing customers of the health risks violates the Tennessee Consumer Protection Act of 1977.
The lawsuit was resolved by Roth denying wrongdoing but voluntarily agreed to stop selling the products.
Attorney General Cooper said:“Although there were no complaints from Tennesseans, we are satisfied the company agreed to stop sales and comply with the law before anyone could be harmed.”
Following an investigation, Roth was accused of having:“illegally manufactured, marketed and sold the eyelash products that contain analogs or derivatives of the drug phostaglandin without FDA approval.”
The settlement specifies that the company will stop selling their eyelash products in the state until they have been authorized by the FDA or declared outside its jurisdiction.
The company was also ordered to make a token payment of $1500.00 to cover attorney’s fees and costs of the investigation.
Prostaglandins are chemical compounds used for medical purposes to lower blood pressure, regulate body temperature and platelet formation, control inflammation and vascular permeability and affect certain hormones.
They are commonly used in cosmetic eyecare products because of their effect of creating longer, thicker lashes. They have been associated very rarely with health problems in some customers.
Although Prostaglandins are legal in the US, the state claims that if Roth wished to include them in their products they needed to obtain approval from the FDA and disclose the fact to customers.
The Tennessee state also settled in February with cosmetics company Nutraluxe LLC, who agreed to stop selling certain of their “Beautylash” products which were found to contain phosphaglandin deriatives or analogs.
Nutraluxe, who retailed their brand through Amazon, also denied wrongdoing as part of the settlement of the lawsuit.